Hi Reg,
yep, I prefer your higher numbers too. Agree re adult dosage being higher - remember, we're going to do an end-run on Ruxolitinib with an inclusion criteria that requires failure of at least one approved therapy & NIH/ BMT CTN seem OK with the restriction.
Cheers
Ann: FDA Grants Orphan Drug Designation for Revascor, page-240
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.015(1.27%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.14 | $6.501M | 5.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 53191 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 200779 | 20 |
View Market Depth
| Last trade - 13.57pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
-0.015 ( 0.31 %) |
||||
| Open | High | Low | Volume | ||
| $1.18 | $1.18 | $1.14 | 1032523 | ||
| Last updated 14.14pm 24/05/2024 ? | |||||
| MSB (ASX) Chart |